Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Cross Country Healthcare (CCRN) over the last 16 years, with Q3 2025 value amounting to $2.2 million.

  • Cross Country Healthcare's Capital Expenditures rose 9492.88% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.9 million, marking a year-over-year decrease of 551.65%. This contributed to the annual value of $8.7 million for FY2024, which is 3764.13% down from last year.
  • As of Q3 2025, Cross Country Healthcare's Capital Expenditures stood at $2.2 million, which was up 9492.88% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Cross Country Healthcare's Capital Expenditures registered a high of $4.0 million during Q2 2023, and its lowest value of $1.1 million during Q3 2024.
  • In the last 5 years, Cross Country Healthcare's Capital Expenditures had a median value of $2.2 million in 2025 and averaged $2.4 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 13849.37% in 2021, then crashed by 6718.25% in 2024.
  • Quarter analysis of 5 years shows Cross Country Healthcare's Capital Expenditures stood at $2.3 million in 2021, then dropped by 11.27% to $2.0 million in 2022, then surged by 42.12% to $2.9 million in 2023, then dropped by 11.97% to $2.5 million in 2024, then decreased by 13.43% to $2.2 million in 2025.
  • Its Capital Expenditures stands at $2.2 million for Q3 2025, versus $2.0 million for Q2 2025 and $1.9 million for Q1 2025.